Science Exchange Scientific Provider Elion Labs Presenting New Research at the AAPS Annual Meeting

November 13, 2017 | Posted by Team in Drug Discovery, Events, New Innovations, Press Release, Research |
  • Breakthrough in drug product particle analysis using machine learning

  • Biopharma researchers can access Elion’s new services from scienceexchange.com

Science Exchange and Elion at AAPS

PALO ALTO, CA, and LOUISVILLE, CO, November 13, 2017 Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development, is proud to announce that Elion Labs, provider of analytical development and drug product characterization services, will present exciting new research at the 2017 AAPS (American Association of Pharmaceutical Scientists) Annual Meeting, the most comprehensive event for innovations in bioanalysis, formulation, and product characterization.

Elion’s expertise has helped bring numerous clinical products to market. Their AAPS research poster presentation (Abstract M8003) introduces a novel method for drug product analysis, using machine learning and advanced image analysis to improve particle detection, enumeration, and classification.

“Machine learning approaches open up exciting new possibilities for analyzing particles in biologics, and ultimately, for better analyzing a broad range of complex data sets,”  said John Gabrielson, Ph.D., CEO and Founding Partner of Elion Labs. “We hope that our research will help biopharmaceutical researchers develop safer, more effective drugs and deliver them to patients faster.”

Elion and Science Exchange will exhibit at booth 2337 at AAPS, meeting drug discovery and development researchers and representatives of regulatory agencies seeking the latest, innovative services available for pharmaceutical analysis.

“We’re proud to participate in this year’s conference alongside Elion, who are true thought leaders in analytical research,” said Elizabeth Iorns, Ph.D., CEO and Co-Founder of Science Exchange. “And because they’re part of the Science Exchange network, biopharmaceutical researchers can access Elion’s technologies immediately under our pre-existing master service agreement that covers IP and confidentiality.”

More information about Elion Labs and their innovative services can be found at www.scienceexchange.com/labs/elion-labs.

 

About Elion Labs

Elion Labs, based in Louisville, Colorado, USA, was founded to serve the analytical development and product characterization needs of the biopharmaceutical industry. Elion offers a variety of services, including analytical method development, qualification and validation; analytical characterization testing of biologics; formulation development; training in highly specialized analytical techniques; comprehensive data analysis including visualization and interpretation of complex data sets; technical and regulatory writing; and technical consulting. They are committed to providing all services with unmatched professionalism, quality, and speed.

About Science Exchange

Science Exchange is the world’s leading and most secure platform for outsourced research, providing an efficient procure-to-pay platform for ordering 6,000+ services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange.

 

 

Elizabeth Iorns, Ph.D., Named 2017 Scrip Award Executive of the Year Finalist

November 1, 2017 | Posted by Team in Company, Events, Press Release, Science Exchange News |

Scrip Award Finalist Elizabeth Iorns

PALO ALTO CA, November 1, 2017 –  Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), announced today that company CEO and co-founder Elizabeth Iorns, Ph.D., has been selected as an Executive of the Year finalist in the prestigious 2017 Scrip Awards.

Dr. Iorns is one of six C-level executives recognized in the Executive of the Year category for private companies or those with a market capitalization of <$1 billion. This awards category acknowledges excellence in the leadership of large and small pharmaceutical and biotechnology companies around the world.

A cancer researcher herself, Iorns co-founded Science Exchange in 2011 to streamline R&D outsourcing and facilitate access to qualified, innovative scientific service providers. Because of the robust platform’s clear benefits to R&D organizations, she has successfully negotiated enterprise-level agreements between Science Exchange and many of the world’s top biopharma companies, as well as with numerous biotech and pharma startup incubators. Over the past year, in addition to expanding the company’s reach into other R&D reliant industries like agrisciences and cosmetics, Iorns led the a successful Series C venture capital funding round, bringing an additional $28 million of investment that will allow Science Exchange to accelerate its impressive growth.

Iorns is also the co-director of the Reproducibility Initiative, and is a part-time partner at Y Combinator. She has a Ph.D. in Cancer Biology from the Institute of Cancer Research (UK), and before starting Science Exchange was an Assistant Professor at the University of Miami, where she remains an Adjunct Professor. She has been recognized previously as one of Nature’s “Ten People that Mattered” and WIRED’s “50 Women Who Are Changing The World.”

In its 13th year, the Scrip Awards program recognizes the key roles that pharmaceutical, biotech and other related industries play in improving healthcare around the world. A panel of 16 highly respected and independent experts from across diverse sectors evaluated the award entries to select the finalists. The winners across 16 categories will be announced at the 13th Annual Scrip Awards ceremony at the London Hilton on Park Lane in London, England on November 29, 2017. For more details on the event, visit www.ScripAwards.com.  

Accelerating Innovation and Mitigating Risk in Outsourced R&D

October 25, 2017 | Posted by Team in Drug Discovery, Events, Outsourcing Best Practices, Science Exchange News, Workshops |

Science Exchange Summit 2017

by Elizabeth Iorns, Ph.D., CEO and Co-Founder, Science Exchange | www.scienceexchange.com

Science Exchange recently hosted a group of procurement executives from multiple industries for our 2017 Science Exchange Outsourced R&D Leadership Summit. During the informative and interactive sessions, we discussed both the challenges and opportunities that organizations are facing as they seek to effectively manage outsourced R&D services.

From presentations by procurement leaders from major pharmaceutical companies on how they’re structuring procurement to enable innovation, to insights on how Science Exchange is pioneering new ways to make it easier to access innovation from our service providers, one of the key themes of the day was the potential for the procurement function to empower scientists to achieve breakthrough discovery. Here are some of my notes around the theme of innovation:

  • Procurement leaders can drive innovation, with the right tools. A pharmaceutical company procurement leader responsible for driving innovation shared that, in less than six months of working with Science Exchange, they had been able to increase their use of new, niche service providers by 11%.
  • Innovation can be hampered by complex processes. Natalie Foote, our Director of Service Provider Operations, presented with two of our service providers — iSpecimen and LabNetwork, a WuXi AppTec company– about new technology integrations with our platform. These integrations allow Science Exchange users to access the iSpecimen and LabNetwork marketplaces through a seamless access point on our platform — no barriers to innovation!
  • Flexible, agile procurement support helps drive innovation. During a panel discussion that I moderated, procurement leaders from three global pharmaceutical companies examined the need to more flexible and agile when it comes to managing R&D requests, and supporting the R&D business through an end-to-end process. They also discussed how their organizations must strategically examine the best mix of internal and external capabilities, core strengths and capacity when it comes to maximizing R&D innovation.

Another theme that surfaced during the Summit was risk mitigation, including the need to better manage confidentiality, data security and intellectual property (IP), and how to prepare for business continuity — whether caused by security breaches or natural disasters. My notes on the theme of risk mitigation:

  • Proactively mitigate risk. During the panel discussion, procurement leaders talked about the need to move beyond a “paper exercise” for managing risk, to a more proactive and rigorous approach to protecting their companies from data and security breaches and business continuity issues. One panelist discussed the drive for holding the business accountable for third-party risk oversight on a global scale, to move beyond that “check the box” mentality.   
  • Balance risk and innovation opportunity. Another panelist emphasized how important it is to strike the delicate balance between managing risk and enabling innovation, to ensure that businesses are protected without slowing down or blocking important scientific discoveries.  
  • Ask the right questions to assess risk. Our Director of Contracts & Compliance, Andrew Gutierrez, highlighted the need to ask the right questions in developing contracts and programs that will protect a company’s confidentiality and IP.He also talked about the need to verify how your data is being protected by your partners to ensure compliance with global regulations.

The Science Exchange Summit gave our entire team an opportunity to deepen our understanding of the needs of global procurement leaders, and our attendees gained insights to bring back to their own organizations, and a network of experts to collaborate with in the future. I look forward to continuing these discussions with our customers so we can continue to learn from one another and accelerate scientific discovery!

Learn more about how Science Exchange can help you — request a demo today.

Science Exchange Honored by Goldman Sachs for Entrepreneurship

October 19, 2017 | Posted by Team in Company, Events, Press Release, Science Exchange News |

Co-Founder and CEO Elizabeth Iorns Among 100 Most Intriguing Entrepreneurs at 2017 Builders + Innovators Summit

Palo Alto, CA – October 19, 2017 – Goldman Sachs (NYSE:GS) is recognizing Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange as one of the 100 Most Intriguing Entrepreneurs of 2017 at its Builders + Innovators Summit in Santa Barbara, California.

Goldman Sachs selected Elizabeth as one of 100 entrepreneurs from multiple industries to be honored at the two-day event.

The life sciences research community has been transformed by Elizabeth’s ability to execute upon her vision to transform the procurement and delivery of outsourced R&D services. Thanks to her tenacity and drive, and her deep understanding of the need for improved R&D efficiency, Science Exchange is enabling breakthrough scientific discoveries by providing researchers with an online platform for efficient access to the world’s best outsourced R&D service providers.

“This is a tremendous honor and I’m excited to be recognized by Goldman Sachs along with these other inspiring entrepreneurs,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange.  “The work our team at Science Exchange has been doing in outsourced R&D is critical for driving scientific breakthroughs and innovation and I’m proud to lead the team in this charge.”

“We are pleased to recognize Elizabeth Iorns as one of the most intriguing entrepreneurs of 2017,” said David M. Solomon, President and Co-Chief Operating Officer at Goldman Sachs. “This is the sixth year that we’ve hosted the Builders + Innovators Summit where emerging business leaders gather to discuss their common interests in building prosperous organizations.”

For more than 145 years, Goldman Sachs has been advising and financing entrepreneurs as they launch and grow their businesses. In addition to honoring 100 entrepreneurs, the Summit consists of general sessions and clinics led by Goldman Sachs experts, seasoned entrepreneurs, academics and business leaders as well as resident scholars.

About Elizabeth Iorns

Elizabeth Iorns, Ph.D., is the CEO and Founder of Science Exchange. Elizabeth Iorns has transformed scientific research by radically improving the procurement and delivery of outsourced research and development (R&D) services. Elizabeth Iorns, Ph.D. (Institute of Cancer Research, London) was an Assistant Professor at University of Miami’s Miller School of Medicine, where she investigated breast cancer development and progression, before launching Science Exchange in 2011. Elizabeth’s work has been featured in multiple media outlets, and she regularly speaks at thought leadership events, such as the 2017 TechCrunch Disrupt event in San Francisco, 2017 Society for Laboratory Automation and Screening annual meeting and the 2016 MassBio CRO/CMO Symposium. Her recent honors include Nature’s “Ten People that Mattered,” WIRED’s “50 Women Who Are Changing The World,” and the “Kauffman Foundation Emerging Entrepreneur Award.” She is a finalist for 2017 Scrip Executive of the Year Award.

About Science Exchange
Science Exchange is the world’s leading and most secure platform for outsourced research, providing an efficient procure-to-pay platform for ordering 6,000+ services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange.

We’re ready for the Charles River’s 23rd Annual Biotech Symposium!

July 26, 2017 | Posted by Team in Conferences, Events, New Innovations, Workshops |

by Annie Chen, Event Marketing Specialist, Science Exchange | www.scienceexchange.com

We are excited to attend the 23rd Annual Biotech Symposium hosted by Charles River, a leading service provider on the Science Exchange network — and we hope to see you there! Join your colleagues and industry experts from Bluebird, Janssen, Pfizer, and Amgen in Carlsbad, CA September 11–13.

With five different session tracks, join Charles River to learn about:

  • Biotherapeutic development programs and related case studies
  • Biomolecules and modifications to prolong a molecule’s half-life
  • Preclinical development of inhaled therapeutics
  • Microphysiology systems for biotherapeutics

Arrive one day early and attend the pre-symposium workshop titled, Where Does My Protein Go and Why Does It Matter? The Role of PK/PD in Biotherapeutics on Sunday, September 10.

Discounted room rates are available until August 11 and special registration fees are available to SOT BTSS members.

Register Now!

Service Providers Aim for Cancer Moonshot at AACR 2017

April 7, 2017 | Posted by Diana Truong in Conferences, Drug Discovery, Events, Helpful products, New Innovations, Research |

Greetings from the AACR Annual Meeting!

This year, we heard Joe Biden’s report on the progress of the Beau Biden Cancer Moonshot Initiative, compared immuno-oncology combination therapies, and mulled over the use of CRISPR screening to finding epigenetically controlled loci.

Joe Biden delivers the Cancer Moonshot Initiative update at AACR 2017

We also checked out the groundbreaking research being done by service providers on the Science Exchange network. Their work directly addresses the recommendations made last fall by the Moonshot’s Blue Ribbon Panel, and we are excited to give cancer researchers rapid access to these technologies through the Science Exchange platform!

Here are a few highlights from our exploration of #AACR17:

First humanized mouse model of tumor growth in bone: Pharmatest and Taconic Biosciences

The Moonshot Initiative’s recommendations specifically called out the potential of humanized mouse models to recapitulate the cellular architecture and heterogeneity found in human tumors. Traditional preclinical models that lack functional interactions between tumor, immune system and microenvironment have not been effective at predicting safety and efficacy of immunomodulating cancer drugs.

Taconic Biosciences showcases its novel animal models at AACR 2017

Pharmatest Services, Ltd. and Taconic Biosciences, both leaders in the development of predictive animal models, presented a poster at AACR 2017 showing the proliferation of human breast cancer cells in the bone injection site of humanized mice. The observed tumor growth, bone remodeling, and infiltration by human immune cells were similar to that seen in human breast cancer patients suffering from bone metastases.

Validation of this mouse model would be a very promising development for preclinical testing of immuno-oncology drug candidates and combination therapies.

 

Mass spectrometry imaging to characterize tumor microenvironment: Imabiotech

Imabiotech’s novel mass spectrometry imaging technology provides better toxicity and efficacy assessments in a number of therapeutic research areas, including immuno-oncology.

One challenge facing the Cancer Moonshot Initiative is that novel technologies are required to address tumor heterogeneity (at the cellular and molecular levels). Thus, the Blue Ribbon Panel called out multiplexed, quantitative imaging as a promising way to connect function with localization.

Imabiotech Corporation is a widely-published expert in the emerging field of mass spectrometry imaging, which is a promising technology to address tumor heterogeneity. Their poster and exhibit at AACR 2017 showcased how mass spectrometry imaging could be used to quantitatively characterize responses to immunotherapy in the tumor microenvironment, with spatial resolution.


Toward 3D patient-derived models of breast cancer, lung cancer, and glioblastoma: KIYATEC, Inc.

Another of the most challenging aspects of oncology is the fact that each patient has a different response to a particular therapy. Recognizing this, the Moonshot Initiative’s recommendations included a call to establish patient-derived test models, such as organoids and xenografts, in which candidate drugs could be tested before treatment.

KIYATEC presents 3D cell-based models for drug response profiling at AACR 2017

KIYATEC, whose expertise lies in generating and using 3D cell-based models for drug response profiling, presented their work on breast cancer, lung cancer, and glioblastoma multiforme (GBM), in three posters at AACR 2017.

One study addressed the challenges facing small cell lung cancer (SCLC) patients, for whom surgical resection is rarely feasible. Therefore, patient-derived tissue is difficult to obtain. KIYATEC was able to isolate functional cancer stem cells and circulating tumor cells, label-free, from SCLC patients, with the aim of developing 3D microtumors from these cells.

KIYATEC also showed that 3D models of breast cancer, which incorporated multiple stromal cell types and immune cells, responded differently to immune checkpoint inhibitors than standard 2D cell culture models. Finally, KIYATEC tackled GBM, for which therapy is particularly confounded by intra-tumor and inter-patient heterogeneity. They developed an efficient method to develop patient-derived 3D models, which may enable more personalized treatments for GBM.

Interested in working with these service providers? Order services on Science Exchange today, or contact us about your project.

Dan Knox, Co-Founder And COO Will Be Speaking At LabLaunch in Monrovia, CA

April 5, 2016 | Posted by Team in Company, Events |

Dan Knox, Co-Founder and COO, will be speaking at LabLaunch in Monrovia, CA, about how to use Science Exchange to order experiments from the world’s best labs. This event is part of the “Biotalk” seminar series which is a monthly educational networking event to support the current and potential biotech entrepreneurs of Los Angeles.
Agendadan
6:00pm-Networking and Refreshments
6:30pm-Presentation
When
Thursday, April 14, 2016 from 6:00 PM to 7:30 PM (PDT)

Where
LabLaunch-Monrovia – 605 Huntington Drive #103, Monrovia, CA 91016

Register

Koliber Biosciences Is Using Science Exchange To Develop Their Probiotic

January 20, 2016 | Posted by Team in Conferences, Events, Small Biotech Stories |

At the Blue Sky Bio Competition held during the SynBioBeta SF 2015 meeting, three finalists presented their ideas to the conference audience. They each hoped to win the prize resources in order to get the boost they needed to bring their ideas to fruition. Science Exchange sponsored this event, and presented the winners with $100,000 in credits to be used on the Science ExchEwa-Lisange platform. In the end, the audience decided to divide the winnings among the three finalists. Ewa Lis, founder and CEO of Koliber Biosciences and one of the winners, presented her ideas about probiotics and depression.

Ewa hopes to tackle the problem of depression. They propose to develop a probiotic strain that will produce a serotonin precursor of tryptophan directly in the gut. A probiotic supplement, especially if available over the counter, is more likely to be accepted by the large population of people that currently avoid medical treatment. It solves the problem of tryptophan degradation in the stomach and doesn’t require long treatment.

The market need for new depression treatments is clear. Depression affects 350 million people worldwide and results in $30 billion of economic loss. Two thirds of people suffering from depression do not seek medical treatment despite the existence of treatments. Moreover many failed treatments are due to patients stopping the medication themselves, often due to side effects.

Ewa and her team will use Science Exchange to develop probiotics that will ameliorate the effects of depression. To develop the strains they will use information from whole genome sequencing, RNA sequencing and analytical chemistry, services readily available via Science Exchange. Combined with their expertise in strain engineering and machine learning, they will be able to leverage the Science Exchange services to accelerate their research.

Science Exchange has many labs that can help Ewa and her team. For DNA sequencing, labs like Macrogen, Laragen, Quick Biology, Affiliated Genetics, ACGT and Applied Biological Materials can perform the work. For RNA sequencing, there are over 60 labs that can help Koliber Biosciences. In addition to these services, Science Exchange has labs that specifically focus on gut microbial community studies such as Second Genome. Lastly, Science Exchange offers many, many labs that perform standard studies such as amino acid analysis and compound synthesis. Science Exchange is the right resource to help Koliber Biosciences get started.

 

Have an idea for a product or company? Enter your idea in the Blue Sky Bio Competition for a chance to win over $500K in prizes.

September 25, 2015 | Posted by Keith Osiewicz in Company, Events |

We at Science Exchange love new ideas, and so we are partnering with SynBioBeta to sponsor the SynBioBeta SF 2015-Blue Sky Bio Competition. If you have an idea for a product, project or new company, please enter the competition by submitting an application. You have a chance of winning $500K in prizes that will help you bring your idea to fruition. Please enter by 12:00 pm PST on October 2nd.Blue-Sky-Bio-Competition

This competition consists of two stages. In the first stage, the judges will review all of the entrants and winnow away the group to 3 finalists. These three finalists will then compete in the second stage of the competition which will take place live and on-stage during the SynBioBeta 2015 conference. You will have 6 minutes to present a PowerPoint presentation describing your idea. The audience will be the judges for this stage of the competition, and they will have 4 minutes to vote for the best idea. Results will be shown live on the stage screen and the 1st, 2nd & 3rd place winners will be displayed.

We are donating $100K in credits to be used on Science Exchange. With these credits the winner can choose from over 4,000 services from over 900 service providers. Our online marketplace enables you to choose your own service providers, or you can use our Concierge service where our friendly team helps you find the right service providers for your project.

The SynBioBeta SF 2015-Blue Sky Bio competition takes place in the in the Robertson Auditorium in the Mission Bay Conference Center on Wednesday, Nov. 4th, from 4:35 to 5:35. Learn more.

Trivia Night at Science Exchange

November 22, 2013 | Posted by Tess Mayall in Events |

 image

Last night, Bay Area biologists, physicists, engineers, and one geologist came together to answer the most pressing scientific questions.

Tesla_circa_1890    Things like (answers are below):

    What is the name of the band that sings Weird Science?

    What two categories did Marie Curie win her Nobel Prize in?   

    Who is in the image to the left?

We were thrilled with the level of knowledge and enthusiasm of the group –       we had no idea that there were such fearsome, science trivia-lites among         us!

A few highlights from the night:

  • Team Darwinners winning first place, after an epic music round naming every science song/artist known to man. Even Thomas Dolby!
  • CEO Elizabeth Iorns’ excited exclamation that Ernest Rutherford was a kiwi.
  • Team Pasteur’s many name changes: Team Pasteur => Pasteur’s Pasture => Pastry => Patrizzle earning them Microryza t-shirts.
  • Everyone learning they’re seasoning their food with halite.

A huge thanks to everyone that came, we’re looking forward to many more to come. Stay tuned!

Answers: Oingo Boingo, Physics and Chemistry, Nikola Tesla

About the author

Tess builds Science Exchange’s online and offline community of scientists and providers. She is a geologist by training, but considers herself a friend of scientists near and far.

 

 

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com